Market Intelligence, Clinical Progress, and High-Purity Reagents for Dyslipidemia and Cardiovascular Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANGPTL3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANGPTL3 Recombinant Protein (Full-Length / N-Terminal Domain) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ANGPTL3 Products |
| Gene Delivery | ANGPTL3 Premade Lentivirus / Promise-ORF Full-length ORF for stable HepG2 or Huh7 cell line construction. |
View ANGPTL3 Products |
| Benchmark Ab | Anti-ANGPTL3 (Evinacumab Sequence) Recombinant human IgG4 positive control. Sequence Verified. |
View ANGPTL3 Products |
| Validator | ANGPTL3 siRNA Set For knockdown verification and assay specificity controls. |
View ANGPTL3 Products |
| Related Target A | ANGPTL8 (Betatrophin) Forms an endogenous regulatory complex with ANGPTL3; critical for combination studies. |
View ANGPTL8 Products |
| Related Target B | PCSK9 Complementary lipid-lowering pathway; emerging clinical rationale for combination therapy. |
View PCSK9 Products |
| Related Target C | ANGPTL4 Parallel angiopoietin-like pathway for selectivity counter-screening. |
View ANGPTL4 Products |
| Related Target D | LPL (Lipoprotein Lipase) Direct downstream interacting enzyme for mechanistic assays. |
View LPL Products |
| Related Target E | APOC3 Triglyceride metabolism regulator for pathway analysis. |
View APOC3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse preclinical evaluation | Human / Cyno / Mouse ANGPTL3 ortholog proteins available with >95% purity; Sequence Verified. |
| Angiopoietin-like family counter-screening | Homolog panel (ANGPTL4, ANGPTL8) proteins strictly verified by mass spec to rule off-target paralog binding. |
| Lack of positive controls | Clinical Benchmark Antibodies (Evinacumab biosimilar) included for assay standardization. |
| Assay specificity & false positives | Validated siRNA included for knockdown verification and specificity checks. |
| Functional blocking & LPL inhibition assays | Native glycosylation via HEK293 expression; Endotoxin controlled to <1 EU/µg for sensitive cellular readouts. |
Live ANGPTL3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ANGPTL3 therapeutics is accelerating beyond rare disease monotherapy. Following the first regulatory approval of a monoclonal antibody (Evinacumab) in homozygous familial hypercholesterolemia (HoFH), the competitive landscape is shifting toward RNAi-based chronic administration and exploration of broader indications such as severe hypertriglyceridemia, nonalcoholic steatohepatitis (NASH), and atherosclerotic cardiovascular disease (ASCVD). As first-generation biologics establish proof-of-concept, the next wave of R&D is targeting hepatic delivery optimization, long-acting subcutaneous formats, and combination regimens with PCSK9 or statin pathways to maximize cardiovascular risk reduction. Achieving these goals requires highly specific epitope mapping to avoid off-target binding with related angiopoietin-like proteins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Regeneron (Approved), Ultragenyx | HoFH, Severe Hypertriglyceridemia | High-affinity binding & LPL functional blockade (Need full-length native antigen) |
| RNAi (siRNA) | Arrowhead Pharmaceuticals, Novartis | Mixed Dyslipidemia, ASCVD | Target engagement & durable knockdown validation (Need ORF Lentivirus & siRNA controls) |
| Antisense Oligonucleotide (ASO) | Ionis / Pfizer (Discontinued), Vinci | Familial Chylomicronemia, Cardiovascular Risk Reduction | Cross-reactive homolog screening & hepatic uptake optimization (Need related target panel) |
| Gene Editing | Verve Therapeutics, Beam Therapeutics | Cardiovascular Prevention | On-target specificity (Need full-length sequence-verified antigen) |
Molecular Differentiation & Assay Strategy
To develop a best-in-class ANGPTL3 therapeutic, the following differentiation dimensions are critical:
- Affinity & Kinetics: ANGPTL3 is a circulating secreted protein; antibodies require high affinity for rapid clearance. For GalNAc-siRNA conjugates targeting the liver, excessive affinity may impair endosomal release. For antibodies, sustained target occupancy is key. Use SPR/BLI for kinetic screening with HEK293-expressed full-length protein to ensure glycosylation-dependent epitope integrity.
- Delivery & Formulation: Chronic disease management demands high-concentration (>100 mg/mL) subcutaneous formulations. Candidates must maintain low viscosity and no aggregation. Conduct high-concentration accelerated stability tests (thermal & interfacial stress) using high-quality, low-endotoxin (<1 EU/µg) antigen.
- Mechanism of Action: Best-in-class antibodies should effectively block ANGPTL3 inhibition of lipoprotein lipase (LPL) and endothelial lipase (EL). Functional assays must go beyond binding; establish LPL activity reversal assays or triglyceride hydrolysis reporter systems using HepG2 overexpression cell lines. TarMart's Lentivirus enables stable ANGPTL3-secreting cell models.
- Safety & Off-target: The C-terminal fibrinogen-like domain (FReD) of the ANGPTL family (ANGPTL1/2/4/6/7) has high sequence homology, posing cross-reactivity risk. Use a panel of ANGPTL paralog proteins (ANGPTL4, ANGPTL8) for rigorous off-target screening via ELISA or SPR. TarMart provides mass-spec-verified paralog proteins.
- Cross-species Reactivity: Preclinical toxicology requires coverage of mouse and cynomolgus monkey. Sequence differences between human, monkey, and mouse ANGPTL3 are mainly in the N-terminal coiled-coil domain; antibody epitopes in this region must be validated for cross-species binding. TarMart offers Human/Cyno/Mouse ortholog proteins with >95% purity and sequence verification.
TarMart Product Strategy Mapping
| Differentiation Need | TarMart Solution (Design Logic) |
|---|---|
| High-quality antigen screening | ANGPTL3 Full-Length Recombinant Protein (HEK293 expressed, native glycosylation; Endotoxin <1 EU/µg; purity >95%; sequence verified) |
| Functional cell model construction | ANGPTL3 ORF Lentivirus / Promise-ORF: Infect HepG2/Huh7 for stable secreting cell lines, enabling LPL activity reversal assays |
| Positive control & PK detection | Evinacumab Sequence Recombinant IgG4: Clinical-grade Benchmark Ab for bridging ELISA, PK detection, and biosimilar comparability studies |
| Specificity validation | ANGPTL3 siRNA Set: Knockdown in cell models to verify target specificity of antibodies or functional readouts |
| Off-target/species screening | ANGPTL4, ANGPTL8, PCSK9, LPL, APOC3 Recombinant Proteins: Paralog and pathway combination targets for cross-reactivity and combination therapy in vitro evaluation |
Related Target Recommendations
Based on pathway synergy and clinical combination trends, cross-sell the following target reagents:
- ANGPTL8 (Betatrophin): Forms an endogenous regulatory complex with ANGPTL3 to co-inhibit LPL. Studying synergistic inhibition or compensatory upregulation is critical for combination therapy.
- PCSK9: Complementary lipid-lowering pathway; combined inhibition with ANGPTL3 can achieve deep reduction in both LDL-C and TG.
- ANGPTL4: Functional homolog that also inhibits LPL but under different regulation (fasting-induced). Essential for selectivity assays to avoid metabolic side effects.
- LPL (Lipoprotein Lipase): Direct downstream enzyme of ANGPTL3. High-purity LPL is essential for constructing functional activity recovery assays.
- APOC3: Another key node in triglyceride metabolism, synergizing with ANGPTL3 to inhibit LPL. Dual inhibition is an emerging direction for refractory hypertriglyceridemia.